The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders

N. Schoenfeld*, O. Epstein, M. Lahav, R. Mamet, M. Shaklai, A. Atsmon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

85 Scopus citations

Abstract

The metabolism of heme is impaired in lymphocytes of patients with malignant lymphoproliferative disorders (MLPO). Two of the enzymes of the heme biosynthetic pathway, delta-aminolevulinic acid dehydrase (ALAD) (EC 4.2.1.24) and ferrochelatase (FC) (EC 4.99.1.1) are markedly reduced. The activity of porphobilinogen deaminase (PBGD) (EC 4.3.1.8) is increased. The rate-limiting enzyme of heme biosynthesis in the liver, aminolevulinate synthase (ALAS) (EC 2.3.1.37) remains unchanged although the concentration of total heme in the lymphocytes is markedly reduced. This might reflect a lack of negative feedback inhibition by heme on ALAS activity in this system.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalCancer Letters
Volume43
Issue number1-2
DOIs
StatePublished - 1 Dec 1988

Funding

FundersFunder number
Israel Cancer Association

    Keywords

    • aminolevulinate synthase
    • heme
    • lymphocytes
    • malignant lymphoproliferative disorders

    Fingerprint

    Dive into the research topics of 'The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders'. Together they form a unique fingerprint.

    Cite this